Phenytoin in Seizure Management
Phenytoin remains an acceptable second-line agent for status epilepticus after benzodiazepines, but newer alternatives like valproate and levetiracetam may offer comparable efficacy with fewer adverse effects, particularly hypotension. 1
Indications
Phenytoin is indicated for:
- Generalized tonic-clonic status epilepticus (second-line after benzodiazepines) 2
- Prevention and treatment of seizures during neurosurgery 2
- Short-term parenteral substitution when oral administration is not possible 2
- Prevention of early post-traumatic seizures (≤7 days) in moderate-severe TBI 3
Phenytoin should NOT be used for:
Dosing Regimen
Loading Dose for Status Epilepticus
Adults:
- 18-20 mg/kg IV at a rate not exceeding 50 mg/min 5, 2, 6
- Infuse over 10-20 minutes (maximum 1 mg/kg/min) 5
Pediatrics:
- 15-20 mg/kg IV at a rate of 1-3 mg/kg/min or 50 mg/min, whichever is slower 5, 2
- Maximum initial dose: 1000 mg 5
Critical administration points:
- Dilute in normal saline only (incompatible with glucose-containing solutions) 5
- Continuous cardiac monitoring is mandatory during infusion 2
- Reduce infusion rate by 50% if heart rate decreases by 10 beats/min 5
Maintenance Dosing
- Start 4-7 mg/kg/day divided every 6-8 hours, beginning after the loading dose 2, 6
- Adjust based on clinical response and serum levels 6
- Therapeutic serum concentration: 10-20 mcg/mL (total), though free phenytoin levels correlate better with efficacy 4
Special Populations
Renal/Hepatic Impairment or Hypoalbuminemia:
- Monitor unbound (free) phenytoin concentrations 2
- Consider reducing infusion rate by 25-50% during loading 7
Pregnancy:
- Phenytoin crosses the placenta and increases risk of congenital malformations 2
- Use only if benefits outweigh risks; monitor free phenytoin levels 2
Neonates:
- Phenobarbital is preferred due to increased toxicity risk from decreased protein binding 5
Monitoring Requirements
During Administration
- Continuous ECG monitoring (risk of bradycardia, heart block, cardiac arrest) 5, 2
- Blood pressure monitoring (risk of hypotension, especially at rates >50 mg/min) 2
- Respiratory function monitoring 2
Therapeutic Drug Monitoring
- Measure serum levels 2-4 hours after loading dose 8
- Second measurement before second maintenance dose (approximately 12 hours) 8
- Free phenytoin levels are preferred in patients with hypoalbuminemia, renal failure, or hepatic disease 4, 9
- Target therapeutic range: 10-20 mcg/mL (total) or 1-2 mcg/mL (free) 9
Ongoing Monitoring
- Complete blood count (risk of hematopoietic complications) 2
- Liver function tests (risk of hepatotoxicity) 2
- Blood glucose (may cause hyperglycemia) 2
Contraindications
Absolute Contraindications
- Hypersensitivity to phenytoin or other hydantoins 2, 10
- Sinus bradycardia, sino-atrial block, second or third-degree AV block, Adams-Stokes syndrome 2
- History of prior acute hepatotoxicity attributable to phenytoin 2
- Coadministration with delavirdine 2
Relative Contraindications (Use with Caution)
- Liver disease (55% of patients with liver disease in one study were taking phenytoin) 10
- Kidney disease 10
- Alcohol use/dependence 10
- Diabetes mellitus 10
- Porphyria (may exacerbate) 2
Drug Interactions
Phenytoin has extensive drug interactions due to:
- High plasma protein binding (90-95%)
- Saturable metabolism
- Potent induction of hepatic enzymes (CYP450) 2
Drugs That Increase Phenytoin Levels
- Amiodarone, fluconazole, isoniazid, sulfonamides, valproate (displaces from protein binding) 2
Drugs That Decrease Phenytoin Levels
- Carbamazepine, rifampin, chronic alcohol use (enzyme induction) 2
Drugs Affected by Phenytoin
- Warfarin (increased metabolism, decreased anticoagulation)
- Oral contraceptives (decreased efficacy)
- Corticosteroids (increased metabolism)
- Other antiseizure medications (variable effects) 2
Important Safety Considerations
Cardiovascular Risks
Hypotension and cardiac arrhythmias are the most serious acute risks, occurring primarily with rapid infusion 1. In comparative studies, 12% of phenytoin patients experienced hypotension versus 0% with valproate 1. This risk necessitates continuous cardiac monitoring and adherence to maximum infusion rates.
Dermatologic Reactions
- Discontinue immediately at first sign of rash unless clearly not drug-related 2
- Risk of Stevens-Johnson syndrome (SJS) and toxic epidermal necrolysis (TEN) 2
- DRESS syndrome (Drug Reaction with Eosinophilia and Systemic Symptoms) can occur 2
Local Toxicity
- Purple glove syndrome can occur with IV administration (extravasation injury) 2
- Intramuscular administration is NOT recommended due to erratic absorption and local toxicity 2
Efficacy Concerns
The 1998 Veterans Affairs study showed only 56% success in terminating status epilepticus when diazepam was followed by phenytoin 1. This modest efficacy has led to consideration of alternatives like valproate and levetiracetam, which showed 68-88% efficacy in comparative trials 1.
Fosphenytoin as Alternative
Fosphenytoin is the preferred parenteral formulation when available due to:
- Lower risk of cardiac adverse effects 5
- Can be administered intramuscularly (therapeutic levels within 30 minutes) 7
- Less risk of local injection site reactions 7
- Can be infused faster (100-150 mg PE/min vs 50 mg/min for phenytoin) 7
Dosing: Same phenytoin equivalents (PE) as phenytoin, but expressed as PE units 7
Clinical Context
While phenytoin has been the traditional second-line agent after benzodiazepines for status epilepticus, the Neurocritical Care Society now recommends valproate, levetiracetam, or phenobarbital in addition to phenytoin/fosphenytoin as acceptable options 1. The choice should be guided by patient-specific factors including cardiac status, pregnancy, and hepatic function. Given phenytoin's narrow therapeutic index, significant drug interactions, and cardiovascular risks, newer agents may be preferable in patients with cardiac disease or those requiring rapid seizure control without hemodynamic compromise.